| Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. | |
| | |
MedLine Citation:
|
PMID: 23319339 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
With the increasing number of available predictive biomarkers clinical management of cancer is becoming increasingly reliant on the accurate serial monitoring of tumor genotypes. We tested whether tumor-specific copy number changes can be inferred from the peripheral blood of patients with cancer. To this end we determined the plasma DNA size distribution and the fraction of mutated plasma DNA fragments with deep sequencing and an ultrasensitive mutation-detection method, i.e. the BEAMing assay. When analyzing the plasma DNA of 32 patients with stage IV colorectal carcinoma (CRC), we found that a subset of the patients (34.4%) had a biphasic size distribution of plasma DNA fragments that was associated with increased circulating tumor cell (CTC) numbers and elevated concentration of mutated plasma DNA fragments. In these cases we were able to establish genome-wide tumor-specific copy number alterations directly from plasma DNA. Thus we could analyze the current copy number status of the tumor genome, which was in some cases many years after diagnosis of the primary tumor. An unexpected finding was that not all patients with progressive metastatic disease appear to release tumor DNA into the circulation in measurable quantities. When we analyzed plasma DNA from 35 patients with metastatic breast cancer we made similar observations suggesting that our approach may be applicable to a variety of tumor entities. This is the first description of such a biphasic distribution in a surprisingly high proportion of cancer patients which may have important implications for tumor diagnosis and monitoring. © 2013 Wiley Periodicals, Inc. |
| | |
Authors:
|
Ellen Heitzer; Martina Auer; Eva Maria Hoffmann; Martin Pichler; Christin Gasch; Peter Ulz; Sigurd Lax; Julie Waldispuehl-Geigl; Oliver Mauermann; Sumitra Mohan; Gunda Pristauz; Carolin Lackner; Gerald Höfler; Florian Eisner; Edgar Petru; Heinz Sill; Hellmut Samonigg; Klaus Pantel; Sabine Riethdorf; Thomas Bauernhofer; Jochen B Geigl; Michael R Speicher |
Related Documents
:
|
15168729 - A small molecule antagonist of the alpha(v)beta3 integrin suppresses mda-mb-435 skeleta... 11448079 - Thallium-201 scintigraphy of neuroblastoma: different results for primary tumors and sk... 6930319 - Definitions of osteosarcoma, chondrosarcoma, and fibrosarcoma of bone. 16365729 - Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immuno... 11717369 - Functional interactions between tumor and peripheral nerve: morphology, algogen identif... 276849 - Morphology of osteosarcoma: new qualitative and quantitative investigations. 9443419 - Persistent human cytomegalovirus infection induces drug resistance and alteration of pr... 17143489 - Induction of anti-tumor immunity by lyophilized myeloma cells secreting gm-csf. 17160409 - Nk cells rapidly remove b16f10 tumor cells in a perforin and interferon-gamma independe... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-15 |
Journal Detail:
|
Title: International journal of cancer. Journal international du cancer Volume: - ISSN: 1097-0215 ISO Abbreviation: Int. J. Cancer Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0042124 Medline TA: Int J Cancer Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2013 UICC. |
Affiliation:
|
Institute of Human Genetics, Medical University of Graz, Harrachgasse 21/8, A-8010 Graz, Austria. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Feasibility Test of Preference-Based Insomnia Treatment for Iraq and Afghanistan War Veterans.
Next Document: Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas.